Savara (SVRA) Competitors $2.98 -0.21 (-6.58%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SVRA vs. KMPH, GLSI, STSA, SYBX, NAMS, AMPH, AKRO, GPCR, SUPN, and MIRMShould you be buying Savara stock or one of its competitors? The main competitors of Savara include Zevra Therapeutics (KMPH), Greenwich LifeSciences (GLSI), Satsuma Pharmaceuticals (STSA), Synlogic (SYBX), NewAmsterdam Pharma (NAMS), Amphastar Pharmaceuticals (AMPH), Akero Therapeutics (AKRO), Structure Therapeutics (GPCR), Supernus Pharmaceuticals (SUPN), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical preparations" industry. Savara vs. Zevra Therapeutics Greenwich LifeSciences Satsuma Pharmaceuticals Synlogic NewAmsterdam Pharma Amphastar Pharmaceuticals Akero Therapeutics Structure Therapeutics Supernus Pharmaceuticals Mirum Pharmaceuticals Zevra Therapeutics (NASDAQ:KMPH) and Savara (NASDAQ:SVRA) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, community ranking, earnings, risk, institutional ownership, valuation, analyst recommendations, dividends and media sentiment. Is KMPH or SVRA more profitable? Savara has a net margin of 0.00% compared to Zevra Therapeutics' net margin of -328.56%. Zevra Therapeutics' return on equity of -16.12% beat Savara's return on equity.Company Net Margins Return on Equity Return on Assets Zevra Therapeutics-328.56% -16.12% -14.17% Savara N/A -58.89%-46.44% Do analysts rate KMPH or SVRA? Savara has a consensus target price of $10.17, suggesting a potential upside of 241.16%. Given Savara's stronger consensus rating and higher possible upside, analysts plainly believe Savara is more favorable than Zevra Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zevra Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Savara 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83 Do institutionals & insiders have more ownership in KMPH or SVRA? 19.4% of Zevra Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 1.1% of Zevra Therapeutics shares are held by insiders. Comparatively, 5.1% of Savara shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has better valuation & earnings, KMPH or SVRA? Zevra Therapeutics has higher revenue and earnings than Savara. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZevra Therapeutics$10.72M0.00-$8.56MN/AN/ASavaraN/AN/A-$54.70M-$0.43-6.93 Does the MarketBeat Community prefer KMPH or SVRA? Zevra Therapeutics received 47 more outperform votes than Savara when rated by MarketBeat users. However, 66.67% of users gave Savara an outperform vote while only 60.74% of users gave Zevra Therapeutics an outperform vote. CompanyUnderperformOutperformZevra TherapeuticsOutperform Votes34560.74% Underperform Votes22339.26% SavaraOutperform Votes29866.67% Underperform Votes14933.33% Which has more volatility and risk, KMPH or SVRA? Zevra Therapeutics has a beta of 2.16, meaning that its stock price is 116% more volatile than the S&P 500. Comparatively, Savara has a beta of 1.02, meaning that its stock price is 2% more volatile than the S&P 500. Does the media prefer KMPH or SVRA? In the previous week, Savara had 22 more articles in the media than Zevra Therapeutics. MarketBeat recorded 26 mentions for Savara and 4 mentions for Zevra Therapeutics. Savara's average media sentiment score of 0.37 beat Zevra Therapeutics' score of 0.00 indicating that Savara is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zevra Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 2 Very Positive mention(s) 7 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral SummarySavara beats Zevra Therapeutics on 9 of the 15 factors compared between the two stocks. Ad Insiders ExposedHas Trump Finally Gone Too Far?Lately, there's been a lot of buzz around a secret loophole executive insiders are using to make millions buying and selling their own stocks. It's so powerful ... so profitable ... that most people immediately assume this is just another example of Trump doing what's best for business executives. But surprisingly, this loophole has been on the books for many years and executives have been using it to make HUNDREDS of millions of dollars. And here's the good news.Register For The Webinar To Discover Get Savara News Delivered to You Automatically Sign up to receive the latest news and ratings for SVRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SVRA vs. The Competition Export to ExcelMetricSavaraPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$511.42M$6.53B$5.15B$8.74BDividend YieldN/A8.16%5.18%4.08%P/E Ratio-6.934.9166.6713.57Price / SalesN/A376.691,276.8487.67Price / CashN/A51.2039.7035.24Price / Book2.579.686.475.93Net Income-$54.70M$154.43M$119.73M$225.73M7 Day Performance-24.94%-9.46%-5.13%-1.34%1 Month Performance-18.36%-7.27%-2.71%1.15%1 Year Performance-20.11%28.13%31.08%24.02% Savara Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SVRASavara1.6373 of 5 stars$2.98-6.6%$10.17+241.2%-17.3%$511.42MN/A-6.93N/AEarnings ReportAnalyst ForecastAnalyst RevisionNews CoverageHigh Trading VolumeKMPHZevra TherapeuticsN/AN/AN/AN/A$200.47M$10.72M0.0022Analyst ForecastNews CoverageGLSIGreenwich LifeSciences2.6013 of 5 stars$13.60+0.2%N/A+16.5%$178.84MN/A-17.223News CoveragePositive NewsSTSASatsuma PharmaceuticalsN/A$1.10-0.9%N/A+0.0%$36.47MN/A-0.5521High Trading VolumeSYBXSynlogic2.9484 of 5 stars$1.42-3.1%N/A-31.7%$16.56M$3.37M-0.346Earnings ReportNews CoverageNAMSNewAmsterdam Pharma3.0191 of 5 stars$24.69-0.3%N/A+150.5%$2.23B$14.09M0.0057Short Interest ↑News CoverageAMPHAmphastar Pharmaceuticals4.88 of 5 stars$46.13-3.3%N/A-20.6%$2.22B$644.40M15.381,761Insider SellingAKROAkero Therapeutics4.0411 of 5 stars$31.61-2.4%N/A+94.5%$2.21BN/A-8.4330Earnings ReportShort Interest ↓Analyst RevisionNews CoverageGPCRStructure Therapeutics2.1962 of 5 stars$36.97flatN/A-28.7%$2.11BN/A-49.29136Analyst RevisionNews CoverageSUPNSupernus Pharmaceuticals2.6821 of 5 stars$38.24+1.1%N/A+27.6%$2.11B$607.52M35.74580Positive NewsMIRMMirum Pharmaceuticals4.2746 of 5 stars$43.58+3.1%N/A+46.8%$2.08B$186.37M-21.57140Earnings ReportAnalyst ForecastInsider SellingAnalyst RevisionNews Coverage Related Companies and Tools Related Companies KMPH Alternatives GLSI Alternatives STSA Alternatives SYBX Alternatives NAMS Alternatives AMPH Alternatives AKRO Alternatives GPCR Alternatives SUPN Alternatives MIRM Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SVRA) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Savara Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Savara With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free SVRA Stock Alerts